Cargando…

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study

Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Salati, Massimiliano, Frega, Giorgio, Merz, Valeria, Caputo, Francesco, Di Federico, Alessandro, Palloni, Andrea, Carloni, Riccardo, Ricci, Angela Dalia, Gadaleta-Caldarola, Gennaro, Messina, Carlo, Spallanzani, Andrea, Gelsomino, Fabio, Benatti, Stefania, Luppi, Gabriele, Melisi, Davide, Dominici, Massimo, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698581/ https://www.ncbi.nlm.nih.gov/pubmed/36363500 http://dx.doi.org/10.3390/medicina58111543

Ejemplares similares

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy
por: Salati, Massimiliano, et al.
Publicado: (2022)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition
por: Medici, Bianca, et al.
Publicado: (2023)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center
por: Rimini, Margherita, et al.
Publicado: (2021)

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

New Horizons for Personalised Treatment in Gastroesophageal Cancer
por: Salati, Massimiliano, et al.
Publicado: (2022)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Optimizing the Continuum of Care in Gastric Cancer
por: Riccò, Beatrice, et al.
Publicado: (2023)

Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience
por: Salati, Massimiliano, et al.
Publicado: (2023)

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
por: Merz, Valeria, et al.
Publicado: (2020)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency
por: Bardasi, Camilla, et al.
Publicado: (2022)

IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
por: Brandi, Giovanni, et al.
Publicado: (2022)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

The Mediterranean Lifestyle to Contrast Low-Grade Inflammation Behavior in Cancer
por: Divella, Rosa, et al.
Publicado: (2023)

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_impg36q92s0s30s0vv42svv8bl